REFERENCES
- All references are to Abstracts from the 10th Conference on Fietroviruses and Opportunistic Infections. February 10–14, 2003. Boston, MA, USA.
- J Ananworanich and others. HIV-NAT 001.4: A Prospective Randomized Trial of Structured Treatment Interruption in Patients with Chronic HIV Infection. Abstract 64 (oral ses-sion).
- M Connors and others. Shifting the Paradigm of Immunologic Control of HIV. Abstract 165 (oral session).
- SG Deeks and others. Continued Reverse Transcriptase Inhibi-tor Therapy is Sufficient to Maintain Short-Term Partial Suppression of Multi-drug Resistant Viremia. Abstract 640 (poster).
- R Draenert and others. Vigorous HIV-specific CD8 T-cell Re-sponses in Late Stage HIV Infection. Abstract 35 (oral session).
- M Dybul and others. A Randomized, Controlled Trial of Long Cycle Structured Intermittent Versus Continuous ARV Therapy for Chronic HIV Infection. Abstract 68Ib (oral ses-sion).
- M Fischer and others. HIV-plasma RNA Rebounds within Days during Structured Treatment Interruptions. Abstract 639 (poster).
- E Harrer and others. Phase-I Study with a Therapeutic MVA-BN-Nef Vaccine in HIV-1 Infected Patients on HAART. Abstract 60 (oral session).
- C Katlama and others. Long-term Benefit of Treatment Inter-ruption in Salvage Therapy (GIGHAART ANRS 097). (oral session).
- J Lawrence and others. CPCRA 064: A Randomized Trial Ex-amining Structured Treatment Interruption for Patients Failing Therapy with Multi-drug Resistant HIV. Abstract 67 (oral session).
- Y Levy and others. Immunological and Virological Efficacy of ALVAC-VIH 1433 and HIV Lipopeptides (Lipo-6T) Com-bined with SC IL-2 in Chronically HIV-infected Patients-Results of the ANRS 093 Randomized Study. Abstract 62 (oral session).
- DA Price and others. Functional Discrepancies in HIV-specific CD8 T-lymphocyte Populations Reflect the Kinetics of Virus Exposure. Abstract 32 (oral session).
- L Ruiz and others. A Multi-center, Randomized Controlled Clini-cal Trial of Continuous vs Intermittent HAART Guided by CD4' T-cell Counts and Plasma HIV-1 RNA Levels. Ab-stract 65 (oral session).
- R Tubiana and others. Therapeutic Vaccination with ALVAC-HIV vCP1433: A Recombinant Canarypox Vaccine in Chronically HIV-1 Infected Patients Treated with HAART: VACCITER (ANRS 094). Abstract 61 (oral session).
- S Vella and others. ISS-PART: A Prospective, Randomized, Multi-center Clinical Trial of Intermittent Therapy in HIV' Subjects with Persistent Suppression of Viral Replication. Abstract 66 (oral session).
- BD Walker and others. Immune Control and Immune Failure in HIV Infection. Abstract 164 (oral session).